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Abstract 
 
Hepatic encephalopathy (HE) is associated with poor quality of life, sharply increased mortality, 
repeated hospitalizations, falls, and motor vehicle accidents. HE manifests with a dynamic 
spectrum of severity. Overt HE is clinically obvious disorientation, even coma. Although 
multiple strategies are available to characterize early stage HE, data are limited validating these 
methods in predicting overt HE, many are impractical in clinical practice, and test cutoffs 
relevant to the average patient clinicians manage are lacking. In order to accurately and 
efficiently classify the risk of overt HE in the population with cirrhosis, novel strategies may be 
needed. Herein, we review the potential competing strategies for the prediction of overt HE. We 
propose refining diagnostic cutoffs for tests designed to define early HE using overt HE as a gold 
standard and expanding prediction tools by using measures of components from the risk pathway 
for HE.  
Introduction 
 
 The prevalence of cirrhosis is rising.(1) Owing to epidemic obesity and nonalcoholic 
fatty liver disease, this trend is expected to accelerate, substantially increasing the global burden 
of persons with cirrhosis and its complications.(2) Among the complications of cirrhosis, none 
are more complex than hepatic encephalopathy (HE). It is associated with poor quality of life 
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(for both patients and caregivers), sharply increased mortality, repeated hospitalizations, falls, 
and motor vehicle accidents.(3-6) A volatile condition, HE is characterized by unpredictable 
changes in cognitive function and progressive disability.(6, 7) HE manifests with a dynamic 
spectrum of severity.(8) Overt HE is clinically obvious; disorientation to person or place or time, 
asterixis, lethargy (grade 2); complete disorientation or somnolence (grade 3);and coma (grade 
4).(9) Early or covert HE is subtler, including deficits in executive function and attention 
(minimal HE) and decreased awareness (grade 1). Compared to patients with cirrhosis without 
HE, even those with early HE are at higher risk of adverse outcomes.(10, 11) Classification of a 
patient’s risk for overt HE may allow for closer monitoring, lifestyle modification, earlier 
treatment, and the opportunity to prevent associated complications such as falls and motor 
vehicle accidents.(12) Although multiple strategies are available to characterize early stage HE, 
data are limited validating these methods in predicting overt HE, many are impractical in clinical 
practice, and test cutoffs relevant to the average patient clinicians manage on a daily basis are 
lacking. In order to accurately and efficiently classify the risk of overt HE in the population with 
cirrhosis, novel strategies may be needed. Herein, we review the potential competing strategies 
for the prediction of overt HE. We propose refining diagnostic cutoffs for tests designed to 
define early HE using overt HE as a gold standard and expanding prediction tools by using 
measures of components from the risk pathway for HE. The HE risk pathway 
Although they are distinct in their clinical presentation, covert and overt HE share a 
common biology. The spectrum of cognitive dysfunction in cirrhosis is predated substantially by 
the development of the risk pathway for HE. Clinically apparent HE is caused by a combination 
of adverse trends in a patient’s peripheral ammonia concentration, burden of inflammation, and 
inter-organ glutamine trafficking.(13) These mechanisms, however, are secondary to other, 
earlier processes, most of which are readily measurable.(Figure 1)  
(1) Above all, as liver dysfunction progresses, the risk of HE rises. This risk can be quantified 
using simple labs and examination findings – the model for endstage liver disease (MELD), 
Child classification, and a score including bilirubin and albumin have each been shown to 
predict the development of HE.(14-16)  
(2) Beyond measures of liver function, portal hypertension (as captured by thrombocytopenia, 
varices, portal manometry) is independently associated with the risk of HE,(17) reflecting 
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increased systemic distribution of neurotoxic substances from the splanchnic circulation via 
portosystemic shunting.  
(3) Owing to skeletal muscle’s role in ammonia metabolism, sarcopenia is associated with 
hyperammonemia and can be observed clinically,(18) measured directly using conventional 
imaging tools.  
(4) The peripheral (shunted) burden of gut bacteria is pro-inflammatory and strongly linked to 
the development of cognitive dysfunction in patients with cirrhosis.(19, 20) The 
gastrointestinal microbiome is accessible at least in the context of research studies and its 
specific constituents are associated with (or causally linked to) the risk of HE.(21, 22) 
Inflammatory cytokines are not routinely measured in clinical practice, however should they 
become commercially available they may discriminate risk for HE.(20) 
(5) Medication lists are easily abstracted from the medical record. Some medication classes may 
modify the gut’s production of ammonia by altering microbial characteristics (i.e. proton 
pump inhibitors), modulating enteric glutaminase activity (i.e. metformin), or by altering gut 
motility (i.e. opioids).(23-25) Other medication classes, namely gabapentinoids and 
benzodiazepines, may exacerbate the neurocognitive effects of cerebral ammonia exposure. 
Predicting the risk of overt HE by identifying covert HE 
Covert HE is a risk factor for the development of overt HE. For this reason, the American 
Association for the Study of Liver Disease recommends that patients with cirrhosis should be 
evaluated for the presence of early grade HE by experienced examiners.(26) Many tools are 
available (Table 1). These include paper-pencil tests (e.g. Portosystemic HE Score; PHES), 
computer programs (EncephalApp), electroencephalography (EEG), and critical flicker fusion 
(CFF). Several factors, however, complicate this recommendation’s clinical implementation. 
First, HE is not always a linear progression from normal to overt HE through covert 
stages.(Figure 1) Many patients without covert HE are at risk for overt HE.(10, 11, 27) In a 
study of 170 patients without a history of overt HE who underwent neuropsychological testing 
for covert HE, Patidar et al found that the 1-year risk of overt HE was 34% in patients with 
covert HE compared to 18% in those without.(10) Although refinements in the evaluation of 
covert HE could improve risk capture, the classification of early grade HE is fundamentally 
complicated by the lack of a true gold-standard. 
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Second, population-based strategies for the evaluation of covert HE are lacking. Having 
been excluded from studies of covert HE, many at-risk patients are not suitable candidates for the 
tools validated to identify cognitive dysfunction in the setting of cirrhosis. This includes patients 
with alcohol use, psychoactive medications, and cardiopulmonary and renal comorbidities,(28) 
clinical factors that may be present in the majority of contemporary patients with cirrhosis.(16) 
The result is a clinically meaningful chasm between efficacy (what can be shown in experimental 
conditions free of confounders) and effectiveness (how a test performs for the patients 
encountered in practice).  
Third, cutoffs for neuropsychological or neurophysiological assessments to predict overt 
HE among real-world patients have not been established. As shown by Bajaj et al(29), tests of 
cognitive function may retain their predictive power in less controlled cohorts, but not with the 
same diagnostic cutoffs or test characteristics. Even in highly selected cohorts, cutoffs suggestive 
of minimal or covert HE vary widely.(30) Each test is internally valid and capable of 
distinguishing covert HE from normal controls in the experimental context but poorly 
generalizable across studies. Insufficiently harmonized test characteristics therefore sharply 
limits external validity. The consequence is unacceptably imprecise outcome prediction. Flud 
and Duarte-Rojo found in a review that the proportion who developed overt HE after a diagnosis 
of minimal HE varied from 10% to 40%.(31)  
Fourth, the grading of neurocognitive status is highly variable between studies. Standard 
psychometric tests (such as the PHES) are graded relative to performance by age and sex 
matched controls.(32) However, normal controls from one center could be interpreted as 
cognitively impaired relative to control performance from another.(27, 30) In our analysis of a 
nationally representative cohort who underwent psychometric testing, we found that factors 
which are unmatched in studies of minimal HE such as education, comorbidities (e.g. diabetes, 
obesity), smoking, and remote alcohol history significantly impact psychometric test 
performance.(30, 33) These differences in control selection between studies are compounded by 
inter-rater variation of test interpretation within studies.(34) 
Fifth, most clinicians do not use neurocognitive tests for a variety of reasons including 
the time required and that the recommended “experienced examiners” are scarce resources.(35)  
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Finally, as it relates to its prognostic implications, the very construct of covert HE which 
lumps minimal with grade 1 HE, is controversial. In two recent prospective studies, a diagnosis 
of grade 1 HE by physical examination has significantly greater long-term prognostic 
significance than a diagnosis of minimal HE determined using psychometric testing.(11, 36) In 
these studies, patients with minimal HE experienced risks of decompensation and death no 
different from those without cognitive impairment.(11, 36) It is, however, challenging for the 
average clinician to discern normal from abnormal cognitive function based on routine clinical 
assessment. In a study examining the classification of standardized patients with various grades 
of HE presented by video,(37) Reuter et al found that half of the hepatologists enrolled (from 
experienced transplant centers) could not distinguish between standardized patients with 
cirrhosis and no HE and those with grade 1 HE. Given these data, ‘covert HE’ may misclassify 
risk through over-diagnosis while particularly diagnoses of grade 1 HE may have imperfect 
inter-rater reliability limiting generalizeability. To resolve this conflict, prospective, multicenter 
comparisons of the relative ability for covert and grade 1 HE to accurately classify the risk of 
overt HE are needed. 
 
 
Predicting the risk of overt HE along HE risk pathways 
An alternative to using the presence of minimal or grade 1 HE as the principle predictor 
of overt HE is risk-pathway based assessments. There are multiple examples. 
(1) The oral glutamine challenge is a physiologic test which captures glutaminase activity and 
excessive peripheral ammonia (reflecting microbial ‘function’) after a glutamine load. Elevated 
ammonia levels after the challenge can predict overt HE.(38) The remaining risk-pathway based 
assessments require prospective validation. 
(2) Clinical scores based on routinely available measures of severity of liver disease are effective 
predictors of overt HE. Either Child class or MELD alone can predict the development of overt 
HE and other important clinical outcomes.(14, 15) We recently developed a risk score – the 
BABS score (Table 1) – based on bilirubin, albumin, nonselective beta-blocker use (reflecting 
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varices), and statin use.(16) Patients with low scores (<0) had an 89% negative predictive value 
for the development of overt HE over the following year.  
(3) Sarcopenia (e.g. low skeletal muscle index at the level of the 3rd
(4) Medication burden is also associated with the development of HE. Prior studies have 
implicated proton pump inhibitors, benzodiazepines, nonselective betablockers.(16, 39, 40) 
Whether these findings causally related or correlated is debatable. Regardless, they are effective 
biomarkers of risk that can be efficiently abstracted at the population level for risk-assessment.    
 lumbar vertebra) has been 
linked with the development of overt HE in a cohort of portosystemic shunt recipients.(18) 
Though promising, data are limited regarding the role of bedside measures of muscle bulk and 
function in this context. Given mounting interest in sarcopenia as a general risk biomarker in 
cirrhosis, such studies are likely highly feasible by collecting data on new HE (and other 
decompensations) in addition to conventional outcomes such as transplant-free survival. 
 
Implementing Outcome Prediction  
Calibration of cutoffs in existing modalities 
Outcomes should be used to calibrate psychometric test cutoffs. However, each modality 
may need multiple test cutoffs for two reasons. First, there are multiple HE-related outcomes of 
value for at-risk patients including overt HE, falls, poor health-related quality of life, and 
mortality.(Figure 1) Second, even the same outcome may need cutoffs tailored to the clinical 
context. Scores that are predictive in decompensated cirrhosis may not provide risk-
discrimination in patients with compensated disease. Furthermore, cutoffs should be lower to 
maximize sensitivity and reduce the risk of false negatives among, for example, transplant-
waitlisted patients with Child C cirrhosis. Conversely, cutoffs should be higher to maximize 
specificity and minimize the risk of a false positive among highly functional patients with Child 
A cirrhosis. Mirroring recommendations for the diagnosis of covert HE,(41) some patients may 
benefit from ‘screening’ using simple tests with cutoffs conditioned to provide high 
sensitivity/negative predictive value followed by tests with cutoffs that aim for 
specificity/positive predictive value. 
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New directions 
 Prediction of HE can utilize established psychometric and neurophysiologic tools but 
could be expanded. First, many elements of the risk pathway for HE can be ascertained at the 
bedside and incorporated as predictors. These include measures of liver function (or medications 
consistent with advanced liver disease), sarcopenia (clinical muscle depletion or radiographic 
evidence),(18) frailty (weakness or disability),(42) portal hypertension (the presence of varices 
or portal pressure), and burden of psychoactive medications.(29) Studies to validate such 
biomarkers must be prospective cohort studies that employ rigorous definitions of HE outcomes 
and should, preferably, compare multiple biomarkers/modalities simultaneously. Second, these 
factors may also serve as targets for therapeutic interventions including improved nutrition (to 
improve or maintain muscle mass), physical therapy or exercise (to improve strength and balance 
to prevent falls), and strategic de-prescribing of psychoactive medications. Accordingly, to 
validate alternative, risk-pathway based predictors of HE in the context of an intervention study 
would involve demonstrating decreased incident HE in patients without (but at-risk for) HE 
(primary prophylaxis) or reduced hospital-days or readmissions in patients with prior overt HE 
(secondary prophylaxis). 
 
Pitfalls for outcome prediction 
 Using outcome prediction as a gold-standard poses 3 main pitfalls. First, existing data for 
overt HE prediction are limited. New prospective studies will be needed but can be 
supplemented with patient-level meta-analyses of published studies. For example, multiple small 
cohorts have been followed after baseline assessment (e.g. inhibitory control test)(30); these 
cohorts can be combined and the pooled risk of overt HE can be used to refine test cutoffs (to 
one that is not defined by cognitive performance but outcome prediction). Second, for each 
strategy there are tradeoffs in accuracy and inclusion related to the test’s simplicity, cost, and 
resource availability. It is unclear how this will impact comparisons across tests. Tests which 
have not been validated in patients taking psychoactive medications, for example, exclude from 
their denominator an important component of the at-risk population. Conversely, tests which 
employ administrative data (such as our score based on billing codes, standard laboratory tests, 
and pharmacy records(16)), apply to more patients but lack potentially important measures of 
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baseline cognitive function. Third, generalizable test-cutoffs are dependent on standardized 
definitions of outcomes which challenging even in the clinical trial setting.(9) “Overt HE” 
defined using administrative data may differ in important ways from “overt HE” discovered in 
prospective research, affecting predictive model characteristics. Similar pitfalls in outcome 
definition will be present for alternative end-points such as motor-vehicle accidents (i.e. self-
reported versus driver registry-based(4)) or quality of life (which can be dynamic). 
 
Conclusions 
The goal of predicting overt HE is to inform patients and implement interventions that 
mitigate the risk of progression. In order to predict overt HE in the population of patients with 
cirrhosis whom we encounter in our clinics, we need new or recalibrated methods that are 
broadly applicable, and validated to predict meaningful outcomes. New data are needed to 
distinguish competing strategies on the basis of their ability to discern risk for adverse events 
that range from the development of overt HE to poor quality of life, falls, admissions, and death. 
An enhanced ability to risk stratify HE will improve the design of intervention studies to mitigate 
these risks. 
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Table: Strengths and Limits of Previously Validated Strategies for the Prediction of Hepatic Encephalopathy  
Domains Factors 
Competing Strategies for the Evaluation of the Risk of Hepatic Encephalopathy 
EEG CFF PHES Encephal-
app 
ICT SIP ANT BABS 
Score 
Child 
Class / 
MELD 
score 
Physical 
exam for 
grade 1 
HE 
Ease of use 
Can be performed at point-
of-care 
- ● - ● ● ● ● ● ● ● 
Takes < 5 minutes 
- - - - - ● ● ● ● ● 
Takes < 10 minutes - ● - ● - ● ● ● ● ● 
Requires trained staff ● ● ● - - - - - - ● 
Special equipment ● ● ● - - - - - - - 
Quality of 
data 
Validated using established 
psychometric tests 
● ● ● ● ● ● ● - - ● 
Cutoffs validated to predict 
outcomes prediction 
- - - - - - - ● ● ● 
Used to predict outcomes ● ● ● ● ● - ● ● ● ● 
Important subgroups 
excluded from prior study 
● ● ● ● ● ● ● - - - 
Test 
characteristics  
Applicable to large 
populations 
- - - - - - - ● ● ● 
High positive predictive 
value for outcomes 
● - - - ● - - - - - 
High negative predictive 
value 
● - - ● ● - - ● ● ● 
ANT= animal naming test (number of unique animals named in 60 seconds(43)); BABS = Bilirubin, Albumin, Beta-Blocker(16), Statin; CFF= critical 
flicker fusion; EEG = electroencephalography; ICT = inhibitory control test; MELD = Model for Endstage Liver Disease, PHES = psychometric 
hepatic encephalopathy score, SIP = sickness impact profile (age, sex, and questions about irritability, appetite, interest in activities, and 
balance(44)). Au
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Figure: The Spectrum of Hepatic Encephalopathy-Related Risks 
 
HE = hepatic encephalopathy, QOL = quality of life 
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